Breaking News Instant updates and real-time market news.

Q

QuintilesIMS

$80.02

0.14 (0.18%)

, BMY

Bristol-Myers

$56.73

-0.03 (-0.05%)

08:03
11/22/16
11/22
08:03
11/22/16
08:03

Quintiles forms new collaboration with Bristol-Myers, Lilly Merck KGaA, Pfizer

QuintilesIMS (Q) announced that it will lead a collaborative initiative involving founding partners Bristol-Myers Squibb (BMY), Eli Lilly (LLY), Merck KGaA (MKGAY), and Pfizer (PFE), which aims to provide clearer and more proactive insight into how anti-cancer treatments are used in a real-world setting across key European markets. "Additional information about how oncology products are actually used, for which types of patients, with what sequences and combinations of therapies, and in which indications, is particularly important to help improve oncology patient care. This new initiative is intended to provide more timely, consistent and comprehensive data resources that could be used to provide further insight for healthcare systems to make better informed decisions on patient care in the future. Importantly, substantial steps have been taken to obtain these insights while respecting individual privacy," the company said.

Q

QuintilesIMS

$80.02

0.14 (0.18%)

BMY

Bristol-Myers

$56.73

-0.03 (-0.05%)

LLY

Eli Lilly

$76.64

-0.03 (-0.04%)

MKGAY

Merck KGaA

$33.37

-0.22 (-0.65%)

PFE

Pfizer

$31.57

0.09 (0.29%)

  • 03

    Dec

  • 04

    Dec

Q QuintilesIMS
$80.02

0.14 (0.18%)

10/05/16
GSCO
10/05/16
INITIATION
Target $94
GSCO
Buy
Quintiles initiated with a Buy at Goldman
Goldman analyst Robert Jones removed his Not Rated designation and added Quintiles to the Buy list with a $94 price target. Jones thinks the strong CRO industry backdrop, modest improvements in win and conversion rates will result in upside to estimates/guidance.
10/05/16
UBSW
10/05/16
NO CHANGE
Target $90
UBSW
Buy
Quintiles price target raised to $90 from $78 at UBS
UBS analyst Jonathan Groberg raised his price target on Quintiles to $90 from $78 following the completion of its merger with IMS Health. The analyst is positive on the stock citing its significant scale in a consolidating industry and near-term strength in its business. Groberg reiterated his Buy rating on Quintiles shares.
10/19/16
JEFF
10/19/16
DOWNGRADE
Target $79
JEFF
Hold
Quintiles downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded Quintiles (Q) to Hold citing concern over the revenue synergy targets from the IMS merger. Windley notes that his firm's survey work indicates sponsors remain skeptical of IMS data's value in speeding clinical trial execution. He lowered his price target for the shares to $79 from $80. The analyst's top picks in Pharmaceutical Services are Charles River (CRL), INC Research (INCR) and PRA Health (PRAH).
10/27/16
PIPR
10/27/16
DOWNGRADE
Target $72
PIPR
Neutral
Quintiles downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Sean Wieland downgraded Quintiles to Neutral saying risks from the merger with IMS are not priced in. Consolidation of data suppliers may increase data acquisition costs in 2018, Wieland tells investors in a research note. Further, he believes the business of clinical trial recruitment will get more challenging. The analyst lowered his price target for Quintiles to $72 from $75.
BMY Bristol-Myers
$56.73

-0.03 (-0.05%)

10/28/16
10/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein saying the stock's valuation now "properly" reflects the challenging fundamental outlook. 2. Bristol-Myers (BMY) upgraded to Long-Term Buy from Neutral at Hilliard Lyons. 3. Qualcomm (QCOM) upgraded on valuation at BMO Capital with analyst Tim Long saying he is neutral on Qualcomm's acquisition of NXP (NXPI), but he expects Qualcomm's stock to stay in a trading range in the wake of the deal. 4. Level 3 (LVTL) upgraded to Outperform from Perform at Oppenheimer with analyst Timothy Horan saying the company has restructured itself in the last few years and now has operational/financial flexibility on free cash flow, with the analyst seeing accelerating growth in 2017. 5. ConocoPhillips (COP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company reported "another solid quarter." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/28/16
HDLY
10/28/16
UPGRADE
HDLY
Long-Term Buy
Bristol-Myers upgraded to Long-Term Buy from Neutral at Hilliard Lyons
11/03/16
JPMS
11/03/16
NO CHANGE
JPMS
JPMorgan calls Lilly, Bristol-Myers, Allergan favorite pharma majors
Following a "challenging" Q3 earnings season for the major pharmaceuticals companies, JPMorgan analyst Chris Schott said pricing continues to be a major overhang on the space. However, he believes these and other challenges are "increasingly well reflected" in both earnings and sector multiples and recommends companies early in new product launch cycles. Coming out of the earnings season, Schott named Eli Lilly (LLY), Bristol-Myers (BMY) and Allergan (AGN) as his favorite names in the large-cap pharma space.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
LLY Eli Lilly
$76.64

-0.03 (-0.04%)

11/03/16
BMOC
11/03/16
NO CHANGE
BMOC
Eli Lilly factored pricing pressure into guidance, says BMO Capital
After meeting with Eli Lilly, BMO Capital analyst Alex Arfaei reports that the company seemed surprised at the intensity of investors' concerns about pricing pressure on it. The analyst says that the company anticipated pricing pressure and factored it into its guidance. The analyst keeps a $91 price target and an Outperform rating on the shares.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.
MKGAY Merck KGaA
$33.37

-0.22 (-0.65%)

08/12/16
BREN
08/12/16
DOWNGRADE
BREN
Hold
Merck KGaA downgraded to Hold from Buy at Berenberg
PFE Pfizer
$31.57

0.09 (0.29%)

11/02/16
LEER
11/02/16
NO CHANGE
LEER
Pfizer boco failure should not spillover to other PCSK9 antibodies, says Leerink
Leerink analyst Geoffrey Porges says that Pfizer's (PFE) announcement that it is discontinuing development of anti-PCSK9 antibody bococizumab is significant and may give investors pause regarding the entire anti-PCSK9 antibody class. However, the analyst notes that composite of views suggests Boco-specific factors led to disappointment and to the program discontinuation. Further, Porges does not believes investors should expect any similar effects in the longer term follow up with Amgen's (AMGN) Repatha or Regeneron (REGN)/Sanofi's (SNY) Praluent.
11/02/16
11/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Hold from Buy at Argus and to Market Perform from Outperform at BMO Capital. 2. BP (BP) downgraded to Hold from Buy at Societe Generale. 3. Corning (GLW) downgraded to Buy from Conviction Buy at Goldman with analyst Doug Clark saying the restocking phase of glass/TV cyclical recovery is now "well understood and largely behind us." 4. Adeptus Health (ADPT) downgraded to Underperform from Buy at BofA/Merrill, to Hold from Buy at Jefferies, and to Equal Weight from Overweight at Stephens. 5. Brookdale Senior Living (BKD) downgraded to Underperform from Neutral at BofA/Merrill, to Market Perform from Outperform at Wells Fargo, and to Outperform from Top Pick at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/16
ARGS
11/02/16
DOWNGRADE
ARGS
Hold
Pfizer downgradedon weaker outlook at Argus
As noted earlier, Argus downgraded Pfizer to Hold from Buy. Analyst Jacob Kilstein cited "recent pipeline setbacks, prospects for increased competition, and management's decision to shelve its business separation plan" as reasons for the downgrade.
11/02/16
BMOC
11/02/16
DOWNGRADE
BMOC
Market Perform
Pfizer downgraded on increased headwinds, uncertainty at BMO Capital
As noted earlier, BMO Capital downgraded Pfizer (PFE) to Market Perform from Outperform. Analyst Alex Arfael says that the company's headwinds, including slowing sales of Ibrance in the U.S. and slower than expected uptake of Prevnar outside the U.S., are intensifying. Additionally, the analyst is less upbeat on Pfizer's IO franchise in the wake of Boco's failure, Target to $33 from $40.

TODAY'S FREE FLY STORIES

IRDM

Iridium

$10.75

0.1 (0.94%)

20:12
06/25/17
06/25
20:12
06/25/17
20:12
Hot Stocks
Iridium confirms successful second launch of Iridium NEXT satellites »

Iridium Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKTDY

Takata

$3.15

1.2199 (63.21%)

20:08
06/25/17
06/25
20:08
06/25/17
20:08
Periodicals
Takata files for bankruptcy in U.S., Bloomberg says »

Takata has filed for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEAS

SeaWorld

$15.65

-0.16 (-1.01%)

20:01
06/25/17
06/25
20:01
06/25/17
20:01
Hot Stocks
SeaWorld receives subpoenas, forms special committee over 'Blackfish' statements »

SeaWorld stated in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$155.07

1.67 (1.09%)

19:57
06/25/17
06/25
19:57
06/25/17
19:57
Periodicals
Facebook plans to offer TV-quality content by late summer, WSJ says »

Facebook is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

FRO

Frontline

$5.59

0.08 (1.45%)

, GNRT

Gener8 Maritime

$6.12

0.21 (3.55%)

19:50
06/25/17
06/25
19:50
06/25/17
19:50
Periodicals
Frontline abandons plans to buy Gener8, WSJ says »

Frontline (FRO) has…

FRO

Frontline

$5.59

0.08 (1.45%)

GNRT

Gener8 Maritime

$6.12

0.21 (3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$84.83

0.4 (0.47%)

18:46
06/25/17
06/25
18:46
06/25/17
18:46
Hot Stocks
Third Point confirms $3.5B stake in Nestle, urges change at company »

In a letter published…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$74.84

-0.68 (-0.90%)

18:23
06/25/17
06/25
18:23
06/25/17
18:23
Periodicals
Wal-Mart initially clamped down on alcohol, swearing at Jet.com, WSJ says »

After Wal-Mart acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

17:55
06/25/17
06/25
17:55
06/25/17
17:55
Periodicals
EU plans EUR1B fine against Google this week, FT reports »

The EU plans to levy a…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NSRGY

Nestle

$84.83

0.4 (0.47%)

17:37
06/25/17
06/25
17:37
06/25/17
17:37
Periodicals
Dan Loeb's Third Point targets Nestle, Bloomberg says »

Nestle is being targeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNG

Cheniere Energy

$47.62

0.34 (0.72%)

17:27
06/25/17
06/25
17:27
06/25/17
17:27
Hot Stocks
Cheniere Energy announces commencement of Korea Gas LNG contract »

Cheniere Energy and Korea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$39.15

0.1 (0.26%)

, VIAB

Viacom

$34.11

-0.01 (-0.03%)

16:20
06/25/17
06/25
16:20
06/25/17
16:20
Hot Stocks
Box Office Battle: Fifth 'Transformers' film ekes out $45M in franchise low »

Viacom's (VIA)…

VIA

Viacom

$39.15

0.1 (0.26%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

TWX

Time Warner

$99.70

0.3 (0.30%)

DIS

Disney

$104.36

0.14 (0.13%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

SNE

Sony

$38.52

0.11 (0.29%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

GSK

GlaxoSmithKline

$44.29

0.13 (0.29%)

14:42
06/25/17
06/25
14:42
06/25/17
14:42
Hot Stocks
GlaxoSmithKline granted Orphan designation for multiple myeloma treatment »

The FDA granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$25.33

-0.13 (-0.51%)

14:40
06/25/17
06/25
14:40
06/25/17
14:40
Hot Stocks
Biohaven granted Orphan designation for Rett syndrome treatment »

The FDA granted Biohaven…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$56.42

-0.075 (-0.13%)

14:37
06/25/17
06/25
14:37
06/25/17
14:37
Hot Stocks
Eisai unit receives Orphan designation for myelomonocytic leukemia treatment »

The FDA has granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTNR

Partner Communications

$5.25

0.1123 (2.19%)

14:23
06/25/17
06/25
14:23
06/25/17
14:23
Hot Stocks
Partner Communications executes early loan repayments, sees Q2 expense »

Partner Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

14:21
06/25/17
06/25
14:21
06/25/17
14:21
Hot Stocks
RA Pharma: Presentation on complement inhibitors supports continued development »

Ra Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

VSTM

Verastem

$2.32

-0.06 (-2.52%)

14:17
06/25/17
06/25
14:17
06/25/17
14:17
Hot Stocks
Verastem reports long-term follow up data from 'DYNAMO' study »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 29

    Jun

  • 11

    Jul

BMY

Bristol-Myers

$56.64

-0.69 (-1.20%)

14:09
06/25/17
06/25
14:09
06/25/17
14:09
Hot Stocks
Bristol-Myers reports four-year follow up data from 'ELOQUENT-2' study »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 24

    Sep

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

, CELG

Celgene

$134.31

0.63 (0.47%)

14:05
06/25/17
06/25
14:05
06/25/17
14:05
Hot Stocks
Agios Pharmaceuticals reports new data from Phase 1/2 trial of IDHIFA »

Agios Pharmaceuticals…

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

14:00
06/25/17
06/25
14:00
06/25/17
14:00
Hot Stocks
Agios reports updated Phase 2 data on AG-348, sees 1H18 pivotal program »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOW

Intrawest Resorts

$23.65

0.04 (0.17%)

13:53
06/25/17
06/25
13:53
06/25/17
13:53
Hot Stocks
Intrawest Resorts says Hart-Scott-Rodino merger waiting period expires »

Intrawest Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$169.61

-1.07 (-0.63%)

13:31
06/25/17
06/25
13:31
06/25/17
13:31
Periodicals
Cigna could gain over 15% by end of next year, Barron's says »

The GOP healthcare plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$48.03

0.53 (1.12%)

, NKE

Nike

$52.85

0.45 (0.86%)

13:26
06/25/17
06/25
13:26
06/25/17
13:26
Periodicals
Potential Nike-Amazon deal another negative for Foot Locker, Barron's says »

A potential direct-sale…

FL

Foot Locker

$48.03

0.53 (1.12%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

RHT

Red Hat

$99.42

0.54 (0.55%)

13:15
06/25/17
06/25
13:15
06/25/17
13:15
Periodicals
Red Hat may eke out double-digit returns, Barron's says »

Red Hat investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$126.07

-0.16 (-0.13%)

, UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

13:01
06/25/17
06/25
13:01
06/25/17
13:01
Periodicals
Alexion, United Therapeutics worth a look, Barron's says »

After the recent jump in…

ALXN

Alexion

$126.07

-0.16 (-0.13%)

UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.